Review article: The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 15-36

  Chouchana, L ^a,b,c   Narjoz, C ^a,b,c   Beaune, P ^a,b,c   Loriot, M A ^a,b,c   Roblin, X ^d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; 6 THIOGUANINE NUCLEOTIDE; 6 THIOINOSINE MONOPHOSPHATE; 6 THIOINOSINE TRIPHOSPHATE; ABC TRANSPORTER; ALDEHYDE OXIDASE; ALLOPURINOL; ATP BINDING CASETTE SUBFAMILY C MEMBER 4; AZATHIOPRINE; CORTICOSTEROID; DRUG METABOLITE; GLUTATHIONE TRANSFERASE; INFLIXIMAB; INOSINE TRIPHOSPHATASE; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; PHOSPHATASE; PLACEBO; STEROID; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ABDOMINAL PAIN; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CROHN DISEASE; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NODULAR REGENERATIVE HYPERPLASIA; PANCREATITIS; PANCYTOPENIA; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TOXIC HEPATITIS; ULCERATIVE COLITIS; VOMITING;

ALGORITHMS; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; THIOGUANINE;

EID: 83555174812     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04905.x     Document Type: Review

References (235)

1. Elion GB, Hitchings GH, Vanderwerff H,. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 1951; 192: 505-18.
2. Bean RH,. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49: 592-3.
3. Cosnes J, Nion-Larmurier I, Tiret E, Gendre J-P,. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41. (Pubitemid 40139240)
4. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
5. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W,. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87. (Pubitemid 43374543)
6. Travis SPL, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl. 1): i16-35. (Pubitemid 43268291)
7. Pearson DC, May GR, Fick GH, Sutherland LR,. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
8. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;(6):CD000545.
9. Pearson DC, May GR, Fick G, Sutherland LR,. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000067.
10. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M,. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(1):CD000067.
11. Kader HA, Raynor SC, Young R, et al. Introduction of 6-mercaptopurine in Crohn's disease patients during the perioperative period: a preliminary evaluation of recurrence of disease. J Pediatr Gastroenterol Nutr 1997; 25: 93-7. (Pubitemid 27284293)
12. D'Haens G,. Prevention of postoperative recurrence in Crohn's disease. Curr Gastroenterol Rep 1999; 1: 476-81.
13. Cuillerier E, Lémann M, Bouhnik Y, Allez M, Rambaud JC, Modigliani R,. Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol 2001; 13: 1291-6. (Pubitemid 33111973)
14. Travis S,. Azathioprine for prevention of postoperative recurrence in Crohn's disease. Eur J Gastroenterol Hepatol 2001; 13: 1277-9. (Pubitemid 33111969)
15. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-96.
16. Timmer A, McDonald JWD, Macdonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478.
17. Schwab M, Schäffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36. (Pubitemid 34918619)
18. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
19. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-7. (Pubitemid 38373112)
20. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15. (Pubitemid 34267273)
21. Derijks LJJ, Gilissen LPL, Hooymans PM, Hommes DW,. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-29.
22. Eklund BI, Moberg M, Bergquist J, Mannervik B,. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 2006; 70: 747-54. (Pubitemid 44092335)
23. Kurtovic S, Grehn L, Karlsson A, Hellman U, Mannervik B,. Glutathione transferase activity with a novel substrate mimics the activation of the prodrug azathioprine. Anal Biochem 2008; 375: 339-44.
24. Fotoohi AK, Lindqvist M, Peterson C, Albertioni F,. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun 2006; 343: 208-15.
25. Peng X-X, Shi Z, Damaraju VL, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 2008; 32: 799-809. (Pubitemid 351323936)
26. Zaza G, Cheok M, Yang W, et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005; 106: 1778-85. (Pubitemid 41208594)
27. Al Hadithy AFY, de Boer NKH, Derijks LJJ, Escher JC, Mulder CJJ, Brouwers JRBJ,. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37: 282-97. (Pubitemid 41070528)
28. Sahasranaman S, Howard D, Roy S,. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
29. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 1005-9. (Pubitemid 13118706)
30. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-31. (Pubitemid 44476786)
31. Derijks LJJ, Gilissen LPL, Engels LGJB, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-8. (Pubitemid 38703020)
32. Pozler O, Chládek J, Malý J, et al. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohns Colitis 2010; 4: 623-8.
33. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM,. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-63. (Pubitemid 20274115)
34. Fairchild CR, Maybaum J, Kennedy KA,. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986; 35: 3533-41. (Pubitemid 17179198)
35. Lennard L,. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-6. (Pubitemid 34791433)
36. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45. (Pubitemid 36519931)
37. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640-51. (Pubitemid 43023313)
38. Neurath MF, Kiesslich R, Teichgräber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3: 1007-14. (Pubitemid 41415749)
39. Karner S, Shi S, Fischer C, et al. Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy? Ther Drug Monit 2010; 32: 119-28.
40. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005; 312: 537-45. (Pubitemid 40189550)
41. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV,. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001; 61: 5810-6. (Pubitemid 32769099)
42. Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002; 62: 102-9. (Pubitemid 34680521)
43. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004; 10: RA247-54. (Pubitemid 39546047)
44. Woodson LC, Weinshilboum RM,. Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 1983; 32: 819-26. (Pubitemid 13128727)
45. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM,. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1983; 24: 471-8. (Pubitemid 14249844)
46. Remy CN,. Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963; 238: 1078-84.
47. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM,. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 48: 2135-8. (Pubitemid 24359621)
48. Weinshilboum RM, Sladek SL,. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62. (Pubitemid 10061685)
49. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-17. (Pubitemid 38971231)
50. Gisbert JP, Gomollõn F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007; 52: 1262-9. (Pubitemid 46626159)
51. Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 2004; 60: 89-96. (Pubitemid 38626437)
52. Cooper SC, Ford LT, Berg JD, Lewis MJV,. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 2008; 9: 303-9. (Pubitemid 351803933)
53. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73. (Pubitemid 27327100)
54. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30. (Pubitemid 26029354)
55. Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008; 76: 404-15.
56. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M,. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT2-24). Pharmacogenet Genomics 2008; 18: 887-93.
57. Kham SKY, Soh CK, Aw DCW, Yeoh AEJ,. TPMT26 (208F - >L), a novel mutation detected in a Chinese. Br J Clin Pharmacol 2009; 68: 120-3.
58. Appell ML, Wennerstrand P, Peterson C, Hertervig E, Mårtensson L-G,. Characterization of a novel sequence variant, TPMT28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics 2010; 20: 700-7.
59. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM,. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101: 1036-44. (Pubitemid 28125282)
60. Lindqvist M, Haglund S, Almer S, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004; 14: 261-5. (Pubitemid 38530518)
61. Wang L, Pelleymounter L, Weinshilboum R, et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics 2010; 20: 401-5.
62. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE,. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94: 6444-9. (Pubitemid 27270704)
63. Wang L, Sullivan W, Toft D, Weinshilboum R,. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003; 13: 555-64. (Pubitemid 37159634)
64. Krynetski EY, Evans WE,. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-46.
65. Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K,. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17: 65-8. (Pubitemid 36140435)
66. Corominas H, Domènech M, González D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000; 95: 2313-7.
67. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J,. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther 2001; 70: 183-8. (Pubitemid 32777771)
68. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14. (Pubitemid 27172187)
69. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin J-G, Schwab M,. Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 2008; 54: 1637-47.
70. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42. (Pubitemid 29176722)
71. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-87. (Pubitemid 28482633)
72. Lindqvist M, Skoglund K, Karlgren A, et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT3A and identification of a novel sequence variant, TPMT23. Pharmacogenet Genomics 2007; 17: 891-5. (Pubitemid 47462303)
73. Vuchetich JP, Weinshilboum RM, Price RA,. Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genet Epidemiol 1995; 12: 1-11.
74. Roberts RL, Gearry RB, Bland MV, et al. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics 2008; 18: 434-8. (Pubitemid 351535944)
75. Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000; 68: 210-9. (Pubitemid 30659176)
76. Spire-Vayron de la Moureyre C, Debuysère H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12: 177-85. (Pubitemid 28384589)
77. Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154: 814-23.
78. Cheung S-T, Allan RN,. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003; 15: 1245-7. (Pubitemid 38174852)
79. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M,. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498-9.
80. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM,. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 18-25. (Pubitemid 17008125)
81. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM,. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9. (Pubitemid 20229068)
82. Higgs JE, Payne K, Roberts C, Newman WG,. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010; 11: 177-88.
83. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14. (Pubitemid 46216945)
84. Berns A, Rubenfeld S, Rymzo WT, Calabro JJ,. Hazard of combining allopurinol and thiopurine. N Engl J Med 1972; 286: 730-1.
85. Seidman EG,. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 (Suppl. 1): S30-8. (Pubitemid 36395165)
86. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
87. Lemann M, Mary J-Y, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
88. O'Brien JJ, Bayless TM, Bayless JA,. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 39-46.
89. Best WR, Becktel JM, Singleton JW, Kern F Jr,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
90. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1599-604.
91. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-5.
92. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE,. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7. (Pubitemid 9061740)
93. Lemann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8. (Pubitemid 40824692)
94. Jharap B, Seinen ML, de Boer NKH, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-9.
95. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-9.
96. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127: 730-40. (Pubitemid 39208406)
97. Cuffari C, Théorêt Y, Latour S, Seidman G,. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6. (Pubitemid 26338529)
98. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13. (Pubitemid 30171620)
99. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6. (Pubitemid 32378583)
100. Gupta P, Gokhale R, Kirschner BS,. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4. (Pubitemid 33070099)
101. Wright S, Sanders DS, Lobo AJ, Lennard L,. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8. (Pubitemid 38961966)
102. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM,. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-7. (Pubitemid 38561239)
103. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
104. Reinshagen M, Schütz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-14. (Pubitemid 47020987)
105. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-83.
106. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70. (Pubitemid 32989203)
107. Qasim A, Buckley M, O' Morain CA,. Thiopurine metabolites and the role of thiopurine methyltransferase activity in inflammatory bowel disease. Gut 2002; 51:141; author reply 141-2.
108. González-Lama Y, Bermejo F, Lõpez-Sanromán A, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-54.
109. Dewit O, Starkel P, Roblin X,. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 2010; 40: 1037-47.
110. Miheller P, Lakatos PL,. Thiopurines in Crohn's disease, is there something new? Expert Opin Drug Metab Toxicol 2010; 6: 1505-14.
111. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin THJ,. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
112. Ansari A, Elliott T, Baburajan B, et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
113. Rahhal RM, Bishop WP,. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1678-82.
114. van Bodegraven AA, Mulder CJJ,. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol 2006; 12: 6115-23. (Pubitemid 44696108)
115. Szumlanski CL, Weinshilboum RM,. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
116. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 251-7.
117. de Boer NKH, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102: 2747-53. (Pubitemid 350179331)
118. de Graaf P, de Boer NKH, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010; 160: 1083-91.
119. Xin H, Fischer C, Schwab M, Klotz U,. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 1105-9. (Pubitemid 40646536)
120. Dilger K, Schaeffeler E, Lukas M, et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 2007; 29: 1-5. (Pubitemid 46279869)
121. Andrews JM, Travis SPL, Gibson PR, Gasche C,. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009; 29: 459-69.
122. Roblin X, Serre-Debeauvais F, Phelip J-M, Bessard G, Bonaz B,. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 917-25. (Pubitemid 37346676)
123. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE,. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5. (Pubitemid 23245359)
124. Bergan S, Bentdal O, Sødal G, Brun A, Rugstad HE, Stokke O,. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 1997; 19: 502-9. (Pubitemid 28116825)
125. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI,. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9. (Pubitemid 19259182)
126. Kirschner BS,. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21. (Pubitemid 28452927)
127. Gisbert JP, Gomollõn F,. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.
128. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ,. Two cases of thiopurine methyltransferase (TPMT) deficiency - a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 2006; 62: 473-6. (Pubitemid 44401530)
129. Bacon BR, Treuhaft WH, Goodman AM,. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med 1981; 141: 223-6. (Pubitemid 11130262)
130. Lawson DH, Lovatt GE, Gurton CS, Hennings RC,. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 1984; 3: 161-71. (Pubitemid 14001001)
131. Jeurissen ME, Boerbooms AM, van de Putte LB,. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 503-5.
132. Burke DA, Dixon MF, Axon AT,. Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J Clin Gastroenterol 1989; 11: 327-30. (Pubitemid 19147264)
133. Gilissen LPL, Derijks LJJ, Verhoeven HMJH, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007; 39: 182-6. (Pubitemid 46117922)
134. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-8.
135. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301. (Pubitemid 32366982)
136. Schütz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M,. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996; 34: 199-205. (Pubitemid 26107631)
137. Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B,. 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103: 3115-22.
138. Zelinkova Z, Derijks LJJ, Stokkers PCF, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4: 44-9. (Pubitemid 43129523)
139. Campbell S, Kingstone K, Ghosh S,. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16: 389-98. (Pubitemid 34214517)
140. Hartford C, Vasquez E, Schwab M, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007; 67: 4965-72. (Pubitemid 46910205)
141. Dewit O, Moreels T, Baert F, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem 2011; 44: 1062-6.
142. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30. (Pubitemid 30346978)
143. Meggitt SJ, Gray JC, Reynolds NJ,. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367: 839-46. (Pubitemid 43363371)
144. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2. (Pubitemid 36020781)
145. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K,. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87: 108-11. (Pubitemid 28086619)
146. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM,. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119: 985-9.
147. Gisbert JP, González-Lama Y, Maté J,. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-27. (Pubitemid 46976279)
148. de Jong DJ, Derijks LJJ, Naber AHJ, Hooymans PM, Mulder CJJ,. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003; 239: 69-72. (Pubitemid 38112918)
149. Goldstein E, Marion J, Wheeler S, Present D,. 6-Mercaptopurine (6-MP): does it increase or decrease the risks of colon cancer in Crohn's disease (CD)? Gastroenterology 1998; 114 (Suppl. 1): A986.
150. Gold DM, Levine JJ, Weinstein TA, Kessler B, Pettei MJ,. Prolonged medical therapy for severe pediatric ulcerative colitis. Am J Gastroenterol 1995; 90: 732-5.
151. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-82. (Pubitemid 41564356)
152. Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-14. (Pubitemid 47402594)
153. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S,. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-42. (Pubitemid 43972901)
154. Bermejo F, Lõpez-Sanromán A, Algaba A, et al. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 120-4.
155. Gilissen LPL, Derijks LJJ, Bos LP, et al. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004; 16: 705-10. (Pubitemid 38901641)
156. Nygaard U, Toft N, Schmiegelow K,. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 274-81. (Pubitemid 38471553)
157. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM,. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2: 148-59.
158. Goldenberg BA, Rawsthorne P, Bernstein CN,. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-8. (Pubitemid 39237503)
159. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M,. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 220-6. (Pubitemid 38501222)
160. Leong RW, Gearry RB, Sparrow MP,. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf 2008; 7: 607-16.
161. Gearry RB, Day AS, Barclay ML, Leong RWL, Sparrow MP,. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010; 25: 653-5.
162. Shih DQ, Nguyen M, Ibanez P, Kwan LY, Targan SR, Vasiliauskas EA,. W1206 split-dose administration of 6-mercaptopurine/azathioprine: a effective novel strategy for IBD patients with preferential 6mmp metabolism. Gastroenterology 2009; 1: A677-8.
163. Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SHC,. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 654-61.
164. Naber AH, Van Haelst U, Yap SH,. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12: 94-9.
165. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J,. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 287-90. (Pubitemid 32205420)
166. Daniel F, Cadranel J-F, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005; 29: 600-3. (Pubitemid 40825163)
167. Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18: 553-5. (Pubitemid 43832759)
168. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56: 1404-9. (Pubitemid 47517834)
169. Seksik P, Mary J-Y, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011; 17: 565-72.
170. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005; 43: 303-9. (Pubitemid 40956884)
171. Zech CJ, Seiderer J, Reinisch W, et al. Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol 2007; 17: 1898-905. (Pubitemid 46909682)
172. Breen DP, Marinaki AM, Arenas M, Hayes PC,. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005; 11: 826-33. (Pubitemid 40975585)
173. de Boer NKH, Mulder CJJ, van Bodegraven AA,. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 2005; 63: 444-6. (Pubitemid 43019744)
174. Buster EHCJ, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA,. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur J Gastroenterol Hepatol 2008; 20: 68-72. (Pubitemid 350307492)
175. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303. (Pubitemid 36929408)
176. Tanis AA,. Azathioprine in inflammatory bowel disease, a safe alternative? Mediators Inflamm 1998; 7: 141-4. (Pubitemid 28338141)
177. Haber CJ, Meltzer SJ, Present DH, Korelitz BI,. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-6. (Pubitemid 16014606)
178. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9. (Pubitemid 34638866)
179. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9. (Pubitemid 32776509)
180. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA,. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-63. (Pubitemid 36733767)
181. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8. (Pubitemid 37070238)
182. Herrlinger KR, Schwab M, Fellermann K, Stange EF,. 6-thioguanine-buried alive? Gastroenterology 2004; 126: 940-1; author reply 941-2.
183. Domènech E, Nos P, Papo M, Lõpez-San Román A, Garcia-Planella E, Gassull MA,. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005; 40: 52-5.
184. Bowen DG, Selby WS,. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45: 1810-3.
185. Boulton-Jones JR, Pritchard K, Mahmoud AA,. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-5. (Pubitemid 32011729)
186. McGovern DPB, Travis SPL, Duley J, Shobowale-Bakre EM, Dalton HR,. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-9. (Pubitemid 34173838)
187. Holmes SL, Turner BM, Hirschhorn K,. Human inosine triphosphatase: catalytic properties and population studies. Clin Chim Acta 1979; 97: 143-53. (Pubitemid 10241614)
188. Lin S, McLennan AG, Ying K, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J Biol Chem 2001; 276: 18695-701.
189. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111: 360-7. (Pubitemid 36075062)
190. Marsh S, King CR, Ahluwalia R, McLeod HL,. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2004; 49: 579-81. (Pubitemid 39506541)
191. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N,. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006; 52: 240-7. (Pubitemid 43185485)
192. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005; 51: 2282-8. (Pubitemid 41692571)
193. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-72.
194. Stocco G, Crews KR, Evans WE,. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 2010; 9: 23-37.
195. Allorge D, Hamdan R, Broly F, Libersa C, Colombel J-F,. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 2005; 54: 565. (Pubitemid 40395509)
196. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EES, Kuipers EJ, van der Woude CJ,. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005; 54: 1664. (Pubitemid 41531793)
197. Kurzawski M, Dziewanowski K, Lener A, Drozdzik M,. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 2009; 65: 533-40.
198. Gearry RB, Roberts RL, Barclay ML, Kennedy MA,. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14: 779-81. (Pubitemid 39552794)
199. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EES, Van Der Woude CJ,. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26: 643-52. (Pubitemid 47246201)
200. Hobara N, Watanabe A,. Impaired metabolism of azathioprine in carbon tetrachloride-injured rats. Hepatogastroenterology 1981; 28: 192-4. (Pubitemid 11053111)
201. Zhang W, Modén O, Mannervik B,. Differences among allelic variants of human glutathione transferase A2-2 in the activation of azathioprine. Chem Biol Interact 2010; 186: 110-7.
202. Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 57-64. (Pubitemid 46080010)
203. Cotton SC, Sharp L, Little J, Brockton N,. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 7-32. (Pubitemid 30470391)
204. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003; 55: 560-9. (Pubitemid 36783197)
205. Parks DA, Granger DN,. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl 1986; 548: 87-99. (Pubitemid 16090301)
206. Huh K, Yamamoto I, Gohda E, Iwata H,. Tissue distribution and characteristics of xanthine oxidase and allopurinol oxidizing enzyme. Jpn J Pharmacol 1976; 26: 719-24. (Pubitemid 8047360)
207. Ansari A, Aslam Z, De Sica A, et al. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 749-57.
208. Serre-Debeauvais F, Bayle F, Amirou M, et al. Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation. Presse Med 1995; 24: 987-8.
209. Relling MV, Lin JS, Ayers GD, Evans WE,. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-58. (Pubitemid 23001871)
210. Kudo M, Moteki T, Sasaki T, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 2008; 18: 243-51. (Pubitemid 351323239)
211. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 2008; 66: 517-28.
212. Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 375-84.
213. Schwarz G,. Molybdenum cofactor biosynthesis and deficiency. Cell Mol Life Sci 2005; 62: 2792-810. (Pubitemid 41779947)
214. Krenitsky TA, Neil SM, Elion GB, Hitchings GH,. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 1972; 150: 585-99.
215. Clarke DA, Elion GB, Hitchings GH, Stock CC,. Structure-activity relationships among purines related to 6-mercaptopurine. Cancer Res 1958; 18: 445-56.
216. Schwahn B, Rozen R,. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001; 1: 189-201.
217. Karas-Kuzelicki N, Milek M, Mlinaric-Rascan I,. MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females. Clin Biochem 2010; 43: 37-42.
218. Dervieux T, Hancock ML, Pui C-H, et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 2003; 73: 506-16. (Pubitemid 37249121)
219. Brouwer C, De Abreu RA, Keizer-Garritsen JJ, et al. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur J Cancer 2005; 41: 613-23. (Pubitemid 40292742)
220. Sampath J, Adachi M, Hatse S, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002; 4: E14.
221. Krishnamurthy P, Schwab M, Takenaka K, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008; 68: 4983-9.
222. Janke D, Mehralivand S, Strand D, et al. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat 2008; 29: 659-69. (Pubitemid 351614590)
223. Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 2010; 45: 1014-21.
224. FDA. Summary of Product Characteristics: Imuran® [Internet]. Available at:. Accessed July 25, 2011.
225. Roblin X, Oussalah A, Chevaux J-B, Sparrow M, Peyrin-Biroulet L,. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011 [Epub ahead of print].
226. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-91.
227. Lesko LJ,. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84: 301-3.
228. Hanai H, Iida T, Takeuchi K, et al. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Inflamm Bowel Dis 2010; 16: 1376-81.
229. Achkar J-P, Stevens T, Easley K, Brzezinski A, Seidner D, Lashner B,. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 339-45. (Pubitemid 39029175)
230. Andoh A, Tsujikawa T, Ban H, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23: 1373-7.
231. Belaiche J, Desager JP, Horsmans Y, Louis E,. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-6. (Pubitemid 32147184)
232. Kwan LY, Devlin SM, Mirocha JM, Papadakis KA,. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis 2008; 40: 425-32.
233. Erdmann GR, France LA, Bostrom BC, Canafax DM,. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990; 4: 47-51. (Pubitemid 20246250)
234. Lennard L, Singleton HJ,. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992; 583: 83-90.
235. Shipkova M, Armstrong VW, Wieland E, Oellerich M,. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003; 49: 260-8. (Pubitemid 36143448)